amgen earnings are out.iotech giant results now with our meg terrell. >> looking at amgen fourth quarter, a bit of a beat here on adjusted earnings and revenue. eps at $2.16 versus $2.05. now, importantly there also reaffirming their 2015 guidance of $20.8 billion to $21.3 billion in revenue. $9.05 to $9.40 in adjust the earnings per share. it's important they're reaffirming that guidance because so many companies have been getting dinged because of dur currencies. seeing strength from many of their new drugs. a couple of those were from price increases primarily rather than demand. that's going to be interesting to watch. kelly, back to you. >> that's for sure. thank you. our meg terrell covering amgen. it looks like a relatively positive response. the shares up almost 2% after hours. we haven't had as much focus lately on the pharma on the biotech sector. >> but we're going to start to we'll see the numbers come out the rest of this week and into next week. and i'm not necessarily surprised with the amgen

don't worry too much about amgen. it's getting into biosimilars itself. >> i read a little bit about it in the past day or two, a potential breakthrough in the search for antibiotics, an area that's been basically a bermuda triangle for 25 years or so. >> yeah it's one of the biggest public health crises superbugs when bacteria have developed resistance to antibiotics. it means many of our most important drugs won't work meaning common infections could be fatal. drug development hasn't been fast enough. scientists say they've discovered a compound that appears to be able to avoid development of resistance of bacteria and was shown to work well in infections in mice. they found it where a majority of antibiotics were discovered, in nature, but it's stalled in recent years as 99% of what they find proved unable to grow in the lab. it enabled them to test compounds that previously were out of reach for medicine. the antibiotic is still years from potential use in humans but it could be an important step forward in the fi

amgen fell 1%. >>> and some good news for isis pharmaceuticals. johnson & johnson said it will pay the company up to $835 million for the option to license three drug testing targetsing autoimmune diseases in the bowel. j & j fell a fraction to 103.79. >>> morgan stanley fired an employee for stealing data from up to 10% of its wealth management clients, about 350,000 people. so far the bank says there's no evidence of economic loss but account names and numbers were briefly posted online. at least information didn't include social security numbers or passwords. shares of morgan stanley off about 3% today to 37.50. investors got a chance to react to news that holly frontier will take a huge inventory charge. the oil refiner said it would book a pretax charge up to $400 million for the fiscal 2014 year because of the fourth quarter drop in crude oil prices. the stock down more than 4%. it finished at 36.78. >>> 2014 was a record breaking year for money heading into vanyard group. the biggest provider of index tracking mutual funds. according to "th

amgen blew them away, at&t had a pretty good number. electronic arts blew them away.fter the bell. >> and hoping for a 180 compared to tomorrow. apple, they are spending a lot of cash too. charles: 180 billion dollars. >> can you imagine that? we're expecting them to do more acquisitions. we saw the beatz acquisition, more acquisitions will happen, and as we reiterate the apple iwatch into the second and third generations, that's going to generate the watches. charles: the payment system, guys. this payment system has taken off like wildfire. they might have done it again. this might get tim cook out of steve jobs' shadow. >> we're paying by slate with a phone. every number for apple blew away expectations, i bet you it closes up by 10 bucks tomorrow. i own this. charles: apple, it is so covered. i've never seen the stock respond the way it should. wall street will give them the benefit of the doubt. never seen them to the upside to the degree. to matt's point, it should be up minimum of ten points tomorrow. >> because greater china failed. charles: up 100%. >> that w

amgen is trading lower.ended approval of a novartis market drug to copy -- a copy of amg event n's blockbuster cancer drug. so you can see shares both all of them at least showing volatility in today's trading action. back to you. >>> coming up, phil lebeau is making his way from bakersfield, california to cs in las vegas in a self already driv-driving car. we'll check in with him live mid trip to see how the pair of them are doing. i'm only in my 60's. i've got a nice long life ahead. big plans. so when i found out medicare doesn't pay all my medical expenses, i looked at my options. then i got a medicare supplement insurance plan. [ male announcer ] if you're eligible for medicare, you may know it only covers about 80% of your part b medical expenses. the rest is up to you. call now and find out about an aarp medicare supplement insurance plan, insured by unitedhealthcare insurance company. like all standardized medicare supplement insurance plans it helps pick up some of what medicare doesn't pay. and cou

>> amgen a good quarter, 216 beat business 11 cents. not responding. >> people are saying that -- ever since the gilead deal since the hepatitis c, people are saying companies are now price competitive. remember that? people thought that was the end. i think there's a lot of room for biotech to go up. the quarter may not have been as clean as people think. there were some -- some noise in the quarter but amgen's a very good company, not as good as celgene, biogen regeneron and maybe gilead. it's all about conferences. it's all about drug approvals. and if you don't have one for agio, when it gets downgraded it's going to go down. these are not trading on earnings. they trade on some new drug that comes in. i like regeneron. i think their drug will be one of the big of the drugs ever. >> after yesterday's weakness would you like to see a few more days of downward action? >> it would be great to wash out the optimism because you know what happened here is that we're trying to get this reset going of all of the companies that have a lot of

. >> pete's been an amgen, as well. tremendous opportunity and the mistake people make is these are not your grandfather's and grandmother's stocks. >> again with the grandmas. >> wanted to get peoria, illinois, in. hopefully they didn't fall asleep. >> you just insulted them. >> i'm kidding around. >> awful. >> i think it's really interesting because we talked about the sentiment out there on a day that we've had two market down days. bio tech is the ultimate sentiment. no earnings, it's all about potential of these drugs coming out. i use bio tech as an indicator of market sentiment and kind of actually heartening to see the fact there's a billion worth of deals coming out this week, meaning still positive sentiment. >> real quick -- >> real quick. >> i think there are ten or more. >>> coming up next, it is the social stock that logged serious gains since the start of 2015, behind twitter's stealth rally. >>> later, stocks here in the u.s., back in two. can't say thank you enough. you have made my life special by bein

amgen chowdhry joins me from london.ve a good conversation because i've watched a number of your interviews and they quickly devolve into shout fests and that's not where i'm coming from. all right? >> okay. >> good. so you describe this as an act of war. an act of war to me is the murderous act of killing 12 people who make their lives with pens and pencils. explain. >> well, the french government together with your government and the british, as you know are engaged in a war in syria and iraq before that in afghanistan. and this war is not just being prosecuted by people on the ground. it has propaganda. i think this particular provocation is designed on the one hand to undermine the ideology of the perceived enemy. in other words, to say that your values are less than our value, that we will continue to insult the thing which you hold dearest you, which is the sanctity of the prophet muhammad. >> this is satire. this is taking kernels of truth, growing them in proportion and trying to make a serious political point. a

but the fda have granted the first win to novartis against amgen.hift your thinking in how the fda are going to approach bio similars? >> not at all. there is nothing wrong about bio similars. it is the normal course of business, when patents expire bio similars would come in. that's a healthy thing to have. otherwise, health care costs would be unsustainable. our strategy is constantly moving the standard of care, to come up with better medicines and replace our own medicines. the standard of care in breast cancer today, we have moved this standard of care by introducing a very innovative medicine, by providing additional survival benefits for patients, and we will do the same for our other franchises. that is really what our strategy is about. >> severin, i'm trying to understand where we are in the great debate of the united states of america. the people who buy the drugs are putting pressure on pricing. cancer is an incredibly emotive subject for anyone who suffers from it. i've had it in my family. getting the best drugs at the right time is im

it's in a class that's not the class that everybody talks about, where you see amgen really close toink that the street is underestimating the potential for that drug? >> i think the answer to that question depends enormously on the clinical data we expect to see the completion of the phase three trial in 2016. this is an oral medicine so it's different from the pcsk-9 class which has to be injected. it's called a cetp inhibiter and it works to affect levels of good and bad cholesterol. hopefully in a way that will demonstrate improved cardio vas you lar out -- vascular outcomes. >> simon, do you have a question? >> just to pick up on the conversation you were having about the hepatitis c drugs and the way in which some of the prescription providers have obviously decided to get tougher on some of those bigger drugs and trying to press margins. at the same time today, you have shire doing a deal schwhich obviously takes it onto more boutique drugs at the periphery for which it's able to charge hundreds of thousands of dollars because the belief is that the insurance will allow that t

amgen's earnings topping estimates in part because of its drug imbrel. they're less exposed than other drug makers because only 25% of its sales come from outside of the u.s. i happened to notice the sales number yesterday and it was multibillions in a quarter. they started with nothing and they have got a couple of -- they worked and they were clean. and just watching this was a great thing. i watched the stock go from a dollar to 1500 dollars and u.s. steal beat the street but it warns low oil prices and the strong dollar could negatively impact it's business this year so it suggests potential for higher u.s. spending and results from vmware. topping consensus. the company seeing strong demand for its products that help cut the cost of moving data to the cloud. it's a very expensive move. >> microsoft talking about it. ibm talking about it. >> i need to buy more storage for my iphone. >> yes. >> how do i do that. >> we need to put your credit card in. >> you don't need a password? >> no this is a cnbc thing. >> so then just say forget your password and